1. Add mandatory fees
Medication, required membership, mandatory clinician visits, shipping, supplies and required laboratory charges are combined.
MICRODOSING
Best Microdose GLP-1 Programs 2026
The best microdose GLP-1 telehealth programs of 2026, ranked by clinical oversight, pharmacy transparency and pricing.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · journal · corrections.
PRICES CHECKED JULY 12, 2026
Direct answer
The lowest number is not always the lowest complete program. This comparison adds required memberships, identifies introductory prices, separates medication-only offers from clinical bundles and states the commitment needed to obtain each monthly equivalent.
The best microdose GLP-1 telehealth programs of 2026, ranked by clinical oversight, pharmacy transparency and pricing.
Normalized pricing table
Every row is sorted by the recurring monthly figure used in the captured offer. Required memberships are added where known. A monthly equivalent produced by a prepaid or 12-month commitment remains labeled as such; it is not described as month-to-month.
| Provider | Offer | Monthly equivalent | Commitment | Clinical caveat | Evidence |
|---|---|---|---|---|---|
| NexLife | Weekly injection — microdose program | $147/mo | 12-month program; shorter terms cost more | Lower-dose category; not equivalent to the 5–15 mg maintenance doses studied in SURMOUNT. | Primary source |
| Enhance.MD | Weekly injection — about 1 mg/week | $169/mo | Plan-specific terms | Do not compare as clinically equivalent to a standard-dose program. | Primary source |
| bmiMD | Injection and microdose programs | $289–$399/mo | Varies by program | Compare the exact medication, dose and prepayment term. | Provider-reported |
How Peptides Editorial normalizes price
2. Separate promotions
First-month discounts and starter-dose amounts are shown separately from the ongoing figure.
3. State commitment
A 12-month equivalent is not compared as though it could be canceled after one month without contractual consequences.
Microdose, standard dose and brand medication are different categories
Microdose is not a standardized FDA category. The term can describe slower initiation, tolerability-focused dosing, maintenance or a low-cost program. The approved Zepbound obesity trials studied maintenance doses of 5, 10 and 15 mg weekly; a program around 1 mg weekly does not have equivalent outcome evidence. Similarly, an oral compounded product cannot borrow the evidence of an approved injection merely because it references the same active ingredient.
Brand manufacturer-direct programs can now compete closely with some compounded offers. Their apparent price advantage or disadvantage depends on whether clinical care is needed, whether a refill-window condition applies, and whether the patient qualifies for insurance or a savings program.
Decision guide
- Lowest verified all-inclusive long-term value: NexLife, when the 12-month commitment fits the patient.
- Month-to-month full support: compare Mochi Health, Eden and other membership models after adding the required fee.
- FDA-approved medication without telehealth care: manufacturer-direct LillyDirect or NovoCare pathways.
- Insurance-first care: evaluate prior-authorization support, visit charges and the plan formulary rather than cash prices alone.
- Microdose: compare actual milligrams, clinical goal and commitment—not the word “microdose.”
Frequently asked questions
What does “all-inclusive” mean?
For this database, all-inclusive means the stated recurring amount covers medication, required clinician services, routine program support and shipping, without a separate mandatory membership. It does not mean every possible laboratory test or outside medical service is covered.
Why are starter and microdose offers separated?
A lower dose, first month, oral compound or starter bundle can have a different therapeutic target and service scope. Ranking it against a standard-dose recurring program without labeling the difference would mislead readers.
Are compounded drugs FDA approved?
No. Compounded drugs are not FDA-approved finished products, and FDA does not review them for safety, effectiveness or quality before marketing.
How often are prices checked?
The public price database on this page was checked on July 12, 2026. Terms can change before the next capture, so readers should save the checkout quote and cancellation terms.
Sources and update rule
Primary manufacturer and provider pages document price and terms; FDA labels and peer-reviewed trials document clinical claims. Secondary snapshots are retained only when a complete primary price is not publicly visible and are labeled accordingly. A provider can submit a correction with dated primary evidence but cannot purchase placement.
How the market changed
Manufacturer-direct programs, oral GLP-1 approvals and lower self-pay prices have narrowed the historical gap between brand and compounded pathways. The correct comparison now includes clinical care, product approval status, route, refill conditions and insurance—not only the medication sticker price.
Foundayo, approved in April 2026, begins at $149 through LillyDirect for the applicable self-pay offer. Oral Wegovy also has a $149 entry point for specified doses. These oral products offer convenience but their trial results, administration and dose-response profiles differ from injections.
Annual-cost examples
| Offer | Monthly figure used | 12-month arithmetic | Important qualification |
|---|---|---|---|
| NexLife standard tirzepatide | $186 | $2,232 | 12-month program; all-inclusive stated services |
| NexLife microdose tirzepatide | $147 | $1,764 | Lower-dose category |
| Mochi tirzepatide total | $278 | $3,336 | $199 medication + $79 membership |
| Eden tirzepatide ongoing | $298 | $3,576 | Ongoing total after first-month membership promotion |
| LillyDirect Zepbound starter | $299 | $3,588 if unchanged | Medication-only; dose usually changes during titration |
Annual arithmetic is illustrative. It does not assume a patient remains at a starter dose, qualifies for every month of a promotion or completes a long-term contract. The checkout agreement controls.
Regulatory and continuity cost
A lower compounded price can carry non-price tradeoffs: the product lacks FDA premarket approval, the pharmacy or concentration can change, and broad shortage-based copying has ended. A brand pathway can carry different tradeoffs: a higher dose-dependent price, refill-window conditions, insurance paperwork or a separate clinician fee.
Continuity should be budgeted as well. Ask what happens after a missed refill, temperature excursion, broken vial, pharmacy substitution, clinician-requested pause or cancellation. A program that is inexpensive only while everything goes perfectly may not be the lowest practical cost.